Recent Development of Prodrugs of Gemcitabine
Gemcitabine is a nucleoside analog that has been used widely as an anticancer drug for the treatment of a variety of conditions, including ovarian, bladder, non-small-cell lung, pancreatic, and breast cancer. However, enzymatic deamination, fast systemic clearance, and the emergence of chemoresistan...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Genes |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4425/13/3/466 |
| _version_ | 1797471353515802624 |
|---|---|
| author | Bhoomika Pandit Maksim Royzen |
| author_facet | Bhoomika Pandit Maksim Royzen |
| author_sort | Bhoomika Pandit |
| collection | DOAJ |
| description | Gemcitabine is a nucleoside analog that has been used widely as an anticancer drug for the treatment of a variety of conditions, including ovarian, bladder, non-small-cell lung, pancreatic, and breast cancer. However, enzymatic deamination, fast systemic clearance, and the emergence of chemoresistance have limited its efficacy. Different prodrug strategies have been explored in recent years, seeking to obtain better pharmacokinetic properties, efficacy, and safety. Different drug delivery strategies have also been employed, seeking to transform gemcitabine into a targeted medicine. This review will provide an overview of the recent developments in gemcitabine prodrugs and their effectiveness in treating cancerous tumors. |
| first_indexed | 2024-03-09T19:48:16Z |
| format | Article |
| id | doaj.art-64cdeaf57f9346bfb90f551d60325d1a |
| institution | Directory Open Access Journal |
| issn | 2073-4425 |
| language | English |
| last_indexed | 2024-03-09T19:48:16Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Genes |
| spelling | doaj.art-64cdeaf57f9346bfb90f551d60325d1a2023-11-24T01:18:39ZengMDPI AGGenes2073-44252022-03-0113346610.3390/genes13030466Recent Development of Prodrugs of GemcitabineBhoomika Pandit0Maksim Royzen1Department of Chemistry, University at Albany, 1400 Washington Ave., Albany, NY 12222, USADepartment of Chemistry, University at Albany, 1400 Washington Ave., Albany, NY 12222, USAGemcitabine is a nucleoside analog that has been used widely as an anticancer drug for the treatment of a variety of conditions, including ovarian, bladder, non-small-cell lung, pancreatic, and breast cancer. However, enzymatic deamination, fast systemic clearance, and the emergence of chemoresistance have limited its efficacy. Different prodrug strategies have been explored in recent years, seeking to obtain better pharmacokinetic properties, efficacy, and safety. Different drug delivery strategies have also been employed, seeking to transform gemcitabine into a targeted medicine. This review will provide an overview of the recent developments in gemcitabine prodrugs and their effectiveness in treating cancerous tumors.https://www.mdpi.com/2073-4425/13/3/466gemcitabineprodrugchemotherapydrug deliveryanticancer agent |
| spellingShingle | Bhoomika Pandit Maksim Royzen Recent Development of Prodrugs of Gemcitabine Genes gemcitabine prodrug chemotherapy drug delivery anticancer agent |
| title | Recent Development of Prodrugs of Gemcitabine |
| title_full | Recent Development of Prodrugs of Gemcitabine |
| title_fullStr | Recent Development of Prodrugs of Gemcitabine |
| title_full_unstemmed | Recent Development of Prodrugs of Gemcitabine |
| title_short | Recent Development of Prodrugs of Gemcitabine |
| title_sort | recent development of prodrugs of gemcitabine |
| topic | gemcitabine prodrug chemotherapy drug delivery anticancer agent |
| url | https://www.mdpi.com/2073-4425/13/3/466 |
| work_keys_str_mv | AT bhoomikapandit recentdevelopmentofprodrugsofgemcitabine AT maksimroyzen recentdevelopmentofprodrugsofgemcitabine |